800-845-6913
Tuteur & Associates, LLC | Knowledge is Power.
February 7, 2008
THURSDAY, Feb. 7 (HealthDay News) — While use of the clotting drug aprotinin (Trasylol) appears safe during on-pump cardiac surgeries, combining it with angiotensin-converting enzyme (ACE) inhibitors during off-pump cardiac surgery shows a significant risk of postoperative kidney dysfunction, British researchers say.
The study was prompted by previous research that noted an association between use of aprotinin — which reduces the risk of bleeding during complicated surgeries — and renal failure. Drug maker Bayer voluntarily suspended worldwide marketing of aprotinin after preliminary findings from a Canadian study (BART) suggested the drug increased the risk of death. That trial was halted in October 2007.
Continue reading, ‘Trasylol and Ace Inhibitors Tied to Kidney Risk with Cardiac Surgeries.’